


DOCKET NO.: CELL-0314/PA552-USW01  
PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Rikki Peter Alexander, et al.

Application No.: 10/576,731

Filing Date: April 20, 2006

For: THIENO-PYRIDINONE DERIVATIVES AS KINASE INHIBITORS

Confirmation No.: 8274

Group Art Unit: 1625

Examiner: Not Yet Assigned

DATE OF DEPOSIT: February 22, 2007

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

*Elizabeth A. McLoud*

TYPED NAME: Elizabeth A. McLoud

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☒ Copies of reference numbers 2 - 35 listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ A copy of reference number 1 on the attached Form PTO 1449 is not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

**DOCKET NO.: CELL-0314/PA552-USW01**  
**PATENT**


- 3 -

- ☐ The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: February 22, 2007

  
Jane E. Inglese  
Registration No. 48,444

WOODCOCK WASHBURN LLP  
Cira Centre  
2929 Arch Street, 12th Floor  
Philadelphia, PA 19104-2891  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

## PATENT

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☒ Copies of reference numbers 2 - 35 listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ A copy of reference number 1 on the attached Form PTO 1449 is not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

- ☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.






<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. CELL-0314/ PA552-USw01	Application No. 10/576,731
	Applicant Rikki Peter Alexander, et al.	
	Filing Date April 20, 2006	Group 1625
		Confirmation No. 8274

**FOREIGN PATENT DOCUMENTS**


Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	2	WO 99/64400 A1	12/16/99	PCT		
	3	WO 2003/033502 A1	04/24/03	PCT		
	4	WO 2004/014920 A1	02/19/04	PCT		
	5	WO 2005/042540 A1	05/12/05	PCT		
	6	0 324 902	02/03/80	GB		
	7	0 402 918	12/14/33	GB		
	8	0 416 934	09/24/34	GB		
	9	285 356 A5	06/16/89	DD	X abstract	

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. CELL-0314/ PA552-USw01	Application No. 10/576,731
		Applicant Rikki Peter Alexander, et al.	
		Filing Date April 20, 2006	Group 1625
		Confirmation No. 8274	
<b>NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
10	Adams, J.L., et al., "p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines," <u>Progress in Medicinal Chemistry</u> , King, F.D., et al. (Eds.), Elsevier Science, 2001, Vol. 38, 1-60		
11	Adhikari, R., et al., "An adventitious synthesis of 2,2'-dipyrryl disulfides," <u>Australian J. Chem.</u> , 1999, 52, 63-67		
12	Albright, J.D., et al., "The use of $\alpha$ -(Aryl)-morpholineacetonitriles (masked acyl anion equivalents) in 1,4-additions to $\alpha\beta$ -unsaturated esters and nitriles. A versatile synthetic route to 6-aryl-3-(2H)pyridazinones," <u>J. Heterocycl. Chem.</u> , 1978, 15, 881-892		
13	Allen, M., et al., "Deficiency of the stress kinase p38 $\alpha$ results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells," <u>J. Exp. Med.</u> , 2000, 191, 859-869		
14	Badger, A.M., et al., "Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function," <u>J. Pharmacol. Exp. Ther.</u> , 1996, 279(3), 1453-1461		
15	Cohen, P., "The search for physiological substrates of MAP and SAP kinases in mammalian cells," <u>Trends Cell Biol.</u> , 1997, 7, 353-361		
16	Dinarello, C.A., "An update on human interleukin-1: from molecular biology to clinical relevance," <u>J. Clinical Immunology</u> , 1985, 5(5), 287-297		
17	Doza, Y.N., et al., "Activation of the MAP kinase homologue RK requires the phosphorylation of Thr-180 and Tyr-182 and both residues are phosphorylated in chemically stressed KB cells," <u>FEBS Lett.</u> , 1995, 364, 223-228		
18	Enslen, H., et al., "Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6," <u>J. Biol. Chem.</u> , 1998, 273(3), 1741-1748		
19	Griswold, D.E., et al., "Pharmacology of cytokine suppressive anti-inflammatory drug binding protein (CSBP), a novel stress-induced kinase," <u>Pharmacol. Commun.</u> , 1996, 7, 323-329		
20	Hale, K.K., et al., "Differential expression and activation of p38 mitogen-activated protein kinase $\alpha$ , $\beta$ , $\gamma$ , and $\delta$ in inflammatory cell lineages," <u>J. Immun.</u> , 1999, 162, 4246-4252		

EXAMINER	DATE CONSIDERED
----------	-----------------



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. CELL-0314/ PA552-USw01	Application No. 10/576,731
	Applicant Rikki Peter Alexander, et al.	
	Filing Date April 20, 2006	Group 1625
Confirmation No. 8274		

**NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

21	Hunter, T., "Protein kinase classification," <u>Methods in Enzymology (Protein Kinase Classification)</u> , Hunter, T., et al. (Eds.), Academic Press, San Diego, 1991, Vol. 200, 3-37
22	Jiang, Y., et al., "Characterization of the structure and function of a new mitogen-activated protein kinase (p38 $\beta$ )," J. Biol. Chem., 1996, 271, 17920-17926
23	Kotlyarov, A., et al., "MAPKAP kinase 2 is essential for LPS-induced TNF- $\alpha$ biosynthesis," Nature Cell Biol., 1999, 1, 94-97
24	Lee, J.C., et al., "A protein kinase involved in the regulation of inflammatory cytokine biosynthesis," Nature (London), 1994, 372, 739-746
25	Lee, J.C., et al., "Inhibition of monocyte IL-1 production by the anti-inflammatory compound, SK&F 86002," Int. J. Immunopharm., 1988, 10(7), 835-843
26	Lee, J.C., et al., "Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors," Annals N.Y. Acad. Sci., 1993, 696, 149-170
27	Mandrup-Poulsen, T., $\beta$ -cell apoptosis stimuli and signaling," Diabetes, 2001, 50(Suppl. 1), 558-563
28	McDonnell, P.C., et al., "Localization of the human stress responsive MAP kinase-like CSAIDs binding protein (CSBP) gene to chromosome 6p21.3/21.2," Genomics, 1995, 28, 301-302
29	Sabauste, M.C., et al., "Infection of a human respiratory epithelial cell line with rhinovirus; Induction of cytokine release and modulation of susceptibility to infection by cytokine exposure," J. Clin. Invest., 1995, 96, 549-557
30	Sont, J.K., et al., "Fully automated assessment of inflammatory cell counts and cytokine expression in bronchial tissue," Am. J. Respir. Crit. Care Med., 2003, 167, 1496-1503
31	Spurlock, L.A., et al., "The nature of the carbonium ion. VIII., Cycloalkyl cations from thiocyanate isomerizations," J. Org. Chem., 1972, 1162-1168
32	Takekawa, M., et al., "A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK," Cell, 1998, 95, 521-530
33	Teran, L.M., et al., "Role of nasal interleukin-8 in neutrophil recruitment and activation in children with virus-induced asthma," Am. J. Respir. Crit. Care Med., 1997, 155, 1362-1366

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------



